by Peter Ciszewski | Aug 7, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Barry Greene, President of Alnylam, provides RNA interference (RNAi) and the first ever new class of innovative medicines to potentially enter the market this...
by Peter Ciszewski | Aug 7, 2018
Acadia Pharmaceuticals and Neuren Pharmaceuticals announced that they have entered into an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. Trofinetide is a novel synthetic...
by Peter Ciszewski | Aug 6, 2018
Ron Cooper, President and CEO of Albireo, provides and overview of progressive familial intrahepatic cholestasis type (PFIC) is a rare condition that affects the liver. PFIC is a rare genetic disorder that is estimated to affect between one in every 50,000 to...
by Peter Ciszewski | Aug 5, 2018
Gail Cawkwell, MD, PhD, Senior Vice President, Medical Affairs at Intercept, discusses the challenges of diagnosing and treating primary biliary cholangitis (PBC), a rare liver disease that is caused by an autoimmune reaction. The autoimmune reaction damages...
by Peter Ciszewski | Aug 4, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses the importance of his company’s support for the BIO International Convention. The Biotechnology...
